203 related articles for article (PubMed ID: 25687083)
21. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
22. [Role of FDG-PET/CT in diffuse large B-cell lymphoma].
Masamoto Y; Kurokawa M
Rinsho Ketsueki; 2021; 62(9):1359-1366. PubMed ID: 34615795
[TBL] [Abstract][Full Text] [Related]
23. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
Li F; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
[TBL] [Abstract][Full Text] [Related]
24. Multimodal deep learning model on interim [
Yuan C; Shi Q; Huang X; Wang L; He Y; Li B; Zhao W; Qian D
Eur Radiol; 2023 Jan; 33(1):77-88. PubMed ID: 36029345
[TBL] [Abstract][Full Text] [Related]
25. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
27. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
Cortés-Romera M; Sabaté-Llobera A; Mercadal-Vilchez S; Climent-Esteller F; Serrano-Maestro A; Gámez-Cenzano C; González-Barca E
Clin Nucl Med; 2014 Jan; 39(1):e46-52. PubMed ID: 23640215
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
30. Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.
Roland V; Bodet-Milin C; Moreau A; Gastinne T; Mahé B; Dubruille V; Maisonneuve H; Juge-Morineau N; Moreau P; Jardel H; Planche L; Mohty M; Moreau P; Harousseau JL; Kraeber-Bodéré F; Le Gouill S
Bone Marrow Transplant; 2011 Mar; 46(3):393-9. PubMed ID: 20577223
[TBL] [Abstract][Full Text] [Related]
31. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
32. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
33. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
34. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
35. Current status of the role of PET imaging in diffuse large B-cell lymphoma.
Moskowitz CH; Schöder H
Semin Hematol; 2015 Apr; 52(2):138-42. PubMed ID: 25805593
[TBL] [Abstract][Full Text] [Related]
36. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
37. [FDG PET/CT FOR TREATMENT RESPONSE ASSESSMENT IN CANCER].
Bar-Shalom R; Rosengarten O; Heching N; Turner Y; Ruchlemer R
Harefuah; 2021 Jul; 160(7):462-467. PubMed ID: 34263575
[TBL] [Abstract][Full Text] [Related]
38. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
Hong J; Lee Y; Park Y; Kim SG; Hwang KH; Park SH; Jeong J; Kim KH; Ahn JY; Park S; Park J; Lee JH
Ann Hematol; 2012 May; 91(5):687-695. PubMed ID: 22008868
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma.
Yi JH; Kim SJ; Choi JY; Ko YH; Kim BT; Kim WS
Hematol Oncol; 2010 Jun; 28(2):57-61. PubMed ID: 19593742
[TBL] [Abstract][Full Text] [Related]
40. [Value of PET/CT after Chemotherapy for Evaluating Therapentic Efficacy of Patients with Diffuse Large B-cell Lymphoma].
Ding CY; Liu HY; Li TN; Xu W; Fang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1013-6. PubMed ID: 26314436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
